Price target
46.360.000.00%
The 13 analysts offering 1-year price forecasts have a max estimate of — and a min estimate of —.
Analyst rating
Based on 15 analysts giving stock ratings in the past 3 months.
EPS
Reported
Estimate
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
TCE2 EPS for the last quarter is −0.72 EUR despite the estimation of −0.73 EUR. In the next quarter EPS is expected to reach −0.77 EUR. Track more of Celldex Therapeutics, Inc. financials and stay on top of what is up with the company.
In the next quarter Celldex Therapeutics, Inc. revenue is expected to reach 859.35 K EUR. Check out Celldex Therapeutics, Inc. revenue and earnings and make informed decisions.
According to analysts, TCE2 price target is 46.36 EUR with a max estimate of 77.49 EUR and a min estimate of 21.52 EUR. Check if this forecast comes true in a year, meanwhile watch Celldex Therapeutics, Inc. stock price chart and keep track of the current situation with TCE2 news and stock market news.
We've gathered opinions of 15 analysts rating TCE2 stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.